Home > Cardiology > AHA 2020 > Acute Coronary Syndrome > PIONEER III trial: Drug-eluting stents comparable

PIONEER III trial: Drug-eluting stents comparable

Presented By
Prof. Alexandra Lansky, Yale School of Medicine, USA
Conference
AHA 2020
Trial
PIONEER III
Among patients with acute and chronic coronary syndromes undergoing percutaneous coronary intervention (PCI), the novel Supreme healing-targeted drug-eluting stent (HT-DES) was as safe and effective as the standard durable polymer DES (DP-DES) over 12 months, according to the results from the PIONEER III trial [1]. Prof. Alexandra Lansky (Yale School of Medicine, USA) presented the primary results of the PIONEER III trial (NCT03168776), which aimed to demonstrate non-inferiority of the HT-DES compared with the standard DP-DES. She explained that the HT-DES emphasises early restoration of endothelial function in order to minimise chronic inflammation by 2 mechanisms: firstly, rapid drug delivery and polymer degradation and, secondly, an electro-grafted base layer that promotes endothelial migration and healing and protects the underlying metallic stent. PIONE...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on